To date, recent studies revealed that GABPB1L and TRIM28 had the potential to be the therapeutic target for TERT promoter mutation‐positive patients with glioblastoma and bladder cancer, respectively.21, 22. The gene discussed is TRIM28; the disease is urinary bladder cancer.